| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to medicine, namely to the influence of liver failure on rifaximin pharmacokinetics. Described application of rifaximin for obtaining a medication for the treatment of a subject, suffering from, subjected to or being at a stage of remission of hepatic encephalopathy (HE), which includes the introduction of rifaximin during the period from approximately 24 weeks to 24 months in a dose of 550 mg twice per day daily.EFFECT: medication makes it possible to reduce a risk of expressed hepatic encephalopathy in the subject.6 cl, 19 tbl, 6 dwg, 4 ex |
